Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen-Reference-Cited by-同舟云学术

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

Published:2014-07-02 Issue:21 Volume:120 Page:3311-3319
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hassan Raffit¹,Sharon Elad²,Thomas Anish¹,Zhang Jingli,Ling Alexander³,Miettinen Markku⁴,Kreitman Robert J.¹,Steinberg Seth M.⁵,Hollevoet Kevin¹,Pastan Ira¹

Affiliation:

1. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda Maryland

2. Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis; National Cancer Institute; National Institutes of Health; Bethesda Maryland

3. Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda Maryland

4. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda Maryland

5. Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda Maryland

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

2. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy;Hassan;Lung Cancer,2010

3. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium;Chang;Cancer Res,1992

4. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers;Chang;Proc Natl Acad Sci U S A,1996

5. Localization of mesothelin in epithelial ovarian cancer;Hassan;Appl Immunohistochem Mol Morphol,2005

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma;Lung Cancer;2024-09

3. Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma;Journal of Surgical Oncology;2024-08-25

4. New Treatment for Pleural Mesothelioma;Haigan;2024-08-20

5. Targeted Therapy in Mesotheliomas: Uphill All the Way;Cancers;2024-05-22